Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Andreeff

Showing results (341-350 of 504) with videos related to

Pageof 51
Sort By:
Leukemia|April 21, 2023
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AMLYannan Jia, Weiguo Zhang, Mahesh Basyal, et al.
American Journal of Hematology|May 13, 2016
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemiaTalha Badar, Damian R Handisides, Juliana M Benito, et al.
The Journal of Clinical Investigation|March 5, 2019
BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironmentSujan Piya, Hong Mu, Seemana Bhattacharya, et al.
Blood|January 5, 2002
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemiaMarina Konopleva, Twee Tsao, Peter Ruvolo, et al.
Cancer Research|May 27, 2010
Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemiaTwee Tsao, Steven Kornblau, Stephen Safe, et al.
American Journal of Hematology|August 25, 2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeTalha Badar, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.
American Journal of Hematology|September 28, 2016
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemiasBrittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid LeukemiasWeiguo Zhang, Li Li, Muharrem Muftuoglu, et al.
Molecular Cancer Therapeutics|March 9, 2017
Focal Adhesion Kinase as a Potential Target in AML and MDSBing Z Carter, Po Yee Mak, Xiangmeng Wang, et al.
Frontiers in Oncology|October 16, 2018
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaPrajwal Boddu, Gautam Borthakur, Mythili Koneru, et al.
Pageof 51

Showing results (341-350 of 504) with videos related to

Sort By:
Pageof 51
Leukemia|April 21, 2023
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AMLYannan Jia, Weiguo Zhang, Mahesh Basyal, et al.
American Journal of Hematology|May 13, 2016
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemiaTalha Badar, Damian R Handisides, Juliana M Benito, et al.
The Journal of Clinical Investigation|March 5, 2019
BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironmentSujan Piya, Hong Mu, Seemana Bhattacharya, et al.
Blood|January 5, 2002
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemiaMarina Konopleva, Twee Tsao, Peter Ruvolo, et al.
Cancer Research|May 27, 2010
Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemiaTwee Tsao, Steven Kornblau, Stephen Safe, et al.
American Journal of Hematology|August 25, 2015
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeTalha Badar, Hagop M Kantarjian, Graciela M Nogueras-Gonzalez, et al.
American Journal of Hematology|September 28, 2016
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemiasBrittany Knick Ragon, Hagop Kantarjian, Elias Jabbour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid LeukemiasWeiguo Zhang, Li Li, Muharrem Muftuoglu, et al.
Molecular Cancer Therapeutics|March 9, 2017
Focal Adhesion Kinase as a Potential Target in AML and MDSBing Z Carter, Po Yee Mak, Xiangmeng Wang, et al.
Frontiers in Oncology|October 16, 2018
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid LeukemiaPrajwal Boddu, Gautam Borthakur, Mythili Koneru, et al.
Pageof 51